Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 691,907 shares, a growth of 218.7% from the January 12th total of 217,077 shares. Based on an average daily trading volume, of 408,500 shares, the short-interest ratio is presently 1.7 days.
Can Fite Biopharma (NYSEAMERICAN:CANF) opened at $2.03 on Monday. Can Fite Biopharma has a 1-year low of $1.24 and a 1-year high of $2.75. The firm has a market capitalization of $34.13, a PE ratio of 6.24 and a beta of 1.79.
Can Fite Biopharma (NYSEAMERICAN:CANF) last posted its earnings results on Monday, November 27th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. Can Fite Biopharma had a negative return on equity of 57.94% and a negative net margin of 2,453.03%.
A number of research analysts have weighed in on CANF shares. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Can Fite Biopharma in a report on Thursday, February 1st. Maxim Group set a $7.00 target price on Can Fite Biopharma and gave the company a “buy” rating in a report on Monday, January 8th.
A hedge fund recently bought a new stake in Can Fite Biopharma stock. Meitav Dash Investments Ltd. acquired a new position in Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned 0.93% of Can Fite Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 5.12% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/19/short-interest-in-can-fite-biopharma-ltd-canf-expands-by-218-7.html.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.